Muva nje, iNovo Nordisk ikhiphe ngokusemthethweni umbiko wayo wezezimali ka-2022. Idatha ibonisa ukuthi ukuthengiswa okuphelele kweNovo Nordisk ngo-2022 kuzofinyelela ku-176.954 billion Danish krone (US $ 24.994 billion, ukuguqulwa kwezinga lokushintshana kumenyezelwe embikweni wonyaka, okufanayo ngezansi), kuze kufike ku-26% unyaka nonyaka, inzuzo yokusebenza izofinyelela ku-74.809 billion Danish krone. (US $10.566 billion), inyuke ngo-28% unyaka nonyaka, kanti inzuzo iyonke izoba izigidigidi ezingama-55.525 zama-Danish krone (amaRandi ayizigidi eziyizinkulungwane ezingu-7.843), inyuke ngo-16% unyaka nonyaka. Ukusebenza kuhlaba umxhwele kakhulu.

Kuvelaphi ukusebenza okuvelele kweNovo Nordisk? Impendulo i-analogue ye-GLP-1. Epayipini lomkhiqizo weNovo Nordisk, imikhiqizo ingahlukaniswa ngezinhlobo ezine: ama-analogue e-GLP-1, i-insulin nama-analogues, izici zokuhlangana namanye ama-hormone e-metabolic, ngokuthengiswa kwe-83.371 billion Danish krone ($ 11.176 billion, ngaphandle kwezinaliti zokunciphisa umzimba), i-52.952 billion yesiDanishi i-krone ($7.479 billion), 11.706 billion Danish krone ($1.653 billion) kanye ne-7.138 billion Danish krone ($1.008 billion), ngokulandelana. Phakathi kwama-analogue e-GLP-1, ukuthengiswa komjovo we-Liraglutide hypoglycemic bekwehla unyaka nonyaka, kuyilapho.I-Semaglutideidonsa amehlo ngokwedlulele, ngokuthengiswa okuphelele kwamadola ayizigidi eziyizinkulungwane eziyi-10.882 ngo-2022.